related documents
- Beneficial effects of ramipril on cardiovascular events in high-risk patients older than 75 years of age: Secondary outcomes from the HOPE trial Conferences
- Benefit of clopidogrel in patients undergoing percutaneous coronary intervention in the CURE trial receiving and not receiving an intracoronary Stent Conferences
- Incremental cost-effectiveness of early and long-term clopidogrel in patients undergoing percutaneous coronary infarction in the CURE trial: The PCI-CURE economic analysis Conferences
- International patterns in the care of acute myocardial infarction patients in the occluded artery trial (OAT): Characteristics of 1,835 screened patients Conferences
- Neurohumoral changes as markers of progressive left ventricular remodeling in systolic heart failure: Results of the neurohumoral substudy of the randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Conferences
- Plasma norepinephrine, predicts 12-year survival in patients with reduced ejection fractions from the studies of left ventricular dysfunction (SOLVD) Conferences
- Plasmin-mediated proteolysis of tissue factor pathway inhibitor: Potential contributing mechanism to rethrombosis despite heparin administration following fibrinolytic therapy Conferences
- Randomized comparison of dalteparin versus unfractionated heparin during percutaneous coronary interventions Conferences
- Six-month mortality rates are lower in patients with an acute coronary syndrome treated with the combination of clopidogrel and a statin than in patients treated with either therapy alone: An analysis from the global registry of acute coronary events Conferences
- What is in the differential diagnosis of a B-type natriuretic peptide level of 1,000 pg/ml? Conferences